S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:AVNS

Avanos Medical (AVNS) Stock Price, News & Analysis

$19.91
+0.01 (+0.05%)
(As of 03/28/2024 ET)
Today's Range
$19.86
$20.13
50-Day Range
$18.43
$19.91
52-Week Range
$17.24
$31.31
Volume
232,956 shs
Average Volume
306,316 shs
Market Capitalization
$919.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Avanos Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
55.7% Upside
$31.00 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$152,960 Sold Last Quarter
Proj. Earnings Growth
33.33%
From $1.38 to $1.84 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

378th out of 938 stocks

Surgical Appliances & Supplies Industry

9th out of 17 stocks

AVNS stock logo

About Avanos Medical Stock (NYSE:AVNS)

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS Stock Price History

AVNS Stock News Headlines

Avanos Medical (NYSE:AVNS) Upgraded to Buy by StockNews.com
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
AVNS Mar 2024 20.000 call
Avanos Medical Q4 2023 Earnings Preview
Avanos Medical, Inc. (AVNS)
New Strong Sell Stocks for January 9th
New Strong Sell Stocks for January 12th
New Strong Sell Stocks for January 16th
Avanos Medical Warns of 4Q, 2024 Sales Shortfalls
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Fax
N/A
Employees
3,771
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$31.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+55.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-61,800,000.00
Pretax Margin
-1.17%

Debt

Sales & Book Value

Annual Sales
$673.30 million
Cash Flow
$2.05 per share
Book Value
$26.63 per share

Miscellaneous

Free Float
44,863,000
Market Cap
$919.84 million
Optionable
Optionable
Beta
0.95
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph F. Woody (Age 58)
    CEO & Director
    Comp: $2.37M
  • Mr. Michael C. Greiner (Age 51)
    Senior VP, CFO & Chief Transformation Officer
    Comp: $940.45k
  • Ms. Mojirade James (Age 57)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $759.53k
  • Mr. Kerr W. Holbrook (Age 56)
    Senior VP, GM of Chronic Care & Chief Commercial Officer
    Comp: $716.87k
  • Mr. John Joseph Hurley
    Principal Accounting Officer & Controller
  • Mr. David Crawford
    VP of FP&A and Investor Relations and Treasurer
  • Ms. Michelle Scharfenberg
    Senior VP and Chief Ethics & Compliance Officer
  • Mr. Scott Galovan
    Vice President of Strategy & Corporate Development
  • John W. Cato
    Vice President of Human Resources
  • Mr. Lee Burnes
    Senior Vice President of Global R&D, Clinical and Medical Affairs

AVNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AVNS shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price target for 2024?

2 brokerages have issued 1 year target prices for Avanos Medical's stock. Their AVNS share price targets range from $31.00 to $31.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2024?

Avanos Medical's stock was trading at $22.43 at the beginning of 2024. Since then, AVNS stock has decreased by 11.2% and is now trading at $19.91.
View the best growth stocks for 2024 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,340,000 shares, an increase of 6.3% from the February 29th total of 1,260,000 shares. Based on an average trading volume of 297,300 shares, the short-interest ratio is currently 4.5 days. Currently, 3.0% of the shares of the stock are short sold.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) posted its quarterly earnings data on Tuesday, February, 20th. The company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.37 by $0.01. The business had revenue of $173.30 million for the quarter, compared to analysts' expectations of $170.43 million. Avanos Medical had a positive trailing twelve-month return on equity of 4.25% and a negative net margin of 8.76%. The business's quarterly revenue was down 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS.

What ETF holds Avanos Medical's stock?

Invesco S&P SmallCap Health Care ETF holds 119,434 shares of AVNS stock, representing 1.06% of its portfolio.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical updated its FY 2024 earnings guidance on Friday, February, 23rd. The company provided earnings per share (EPS) guidance of 1.300-1.450 for the period. The company issued revenue guidance of $685.0 million-$705.0 million.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.67%), Vanguard Group Inc. (11.73%), Dimensional Fund Advisors LP (6.15%), Westwood Holdings Group Inc. (4.63%), Paradice Investment Management LLC (3.56%) and Tributary Capital Management LLC (1.49%). Insiders that own company stock include Julie Ann Shimer, Michael Greiner and Patrick J Oleary.
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AVNS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners